Literature DB >> 32419926

Use of the informational spectrum methodology for rapid biological analysis of the novel coronavirus 2019-nCoV: prediction of potential receptor, natural reservoir, tropism and therapeutic/vaccine target.

Veljko Veljkovic1, Júlia Vergara-Alert2, Joaquim Segalés3,4, Slobodan Paessler5.   

Abstract

A novel coronavirus recently identified in Wuhan, China (SARS-CoV-2) has expanded the number of highly pathogenic coronaviruses affecting humans. The SARS-CoV-2 represents a potential epidemic or pandemic threat, which requires a quick response for preparedness against this infection. The present report uses the informational spectrum methodology to identify the possible origin and natural host of the new virus, as well as putative therapeutic and vaccine targets. The performed in silico analysis indicates that the newly emerging SARS-CoV-2 is closely related to severe acute respiratory syndrome (SARS)-CoV and, to a lesser degree, Middle East respiratory syndrome (MERS)-CoV. Moreover, the well-known SARS-CoV receptor (ACE2) might be a putative receptor for the novel virus as well. Actin protein was also suggested as a host factor that participates in cell entry and pathogenesis of SARS-CoV-2; therefore, drugs modulating biological activity of this protein (e.g. ibuprofen) were suggested as potential candidates for treatment of this viral infection. Additional results indicated that civets and poultry are potential candidates for the natural reservoir of the SARS-CoV-2, and that domain 288-330 of S1 protein from the SARS-CoV-2 represents promising therapeutic and/or vaccine target. Copyright:
© 2021 Veljkovic V et al.

Entities:  

Keywords:  2019-nCoV; MERS; SARS; Wuhan coronavirus

Year:  2020        PMID: 32419926      PMCID: PMC7202090.4          DOI: 10.12688/f1000research.22149.4

Source DB:  PubMed          Journal:  F1000Res        ISSN: 2046-1402


  24 in total

1.  Ibuprofen attenuates interleukin-1β-induced inflammation and actin reorganization via modulation of RhoA signaling in rabbit chondrocytes.

Authors:  Rui Li; Xiongbo Song; Gaoming Li; Zhen Hu; Li Sun; Cheng Chen; Liu Yang
Journal:  Acta Biochim Biophys Sin (Shanghai)       Date:  2019-09-06       Impact factor: 3.848

2.  Tissue distribution of ibuprofen in a fatal overdose.

Authors:  G W Kunsman; T P Rohrig
Journal:  Am J Forensic Med Pathol       Date:  1993-03       Impact factor: 0.921

3.  Ibuprofen as a template molecule for drug design against Ebola virus.

Authors:  Slobodan Paessler; Cheng Huang; Milan Sencanski; Nevena Veljkovic; Vladimir Perovic; Sanja Glisic; Veljjko Veljkovic
Journal:  Front Biosci (Landmark Ed)       Date:  2018-01-01

4.  Human coronavirus EMC does not require the SARS-coronavirus receptor and maintains broad replicative capability in mammalian cell lines.

Authors:  Marcel A Müller; V Stalin Raj; Doreen Muth; Benjamin Meyer; Stephan Kallies; Saskia L Smits; Robert Wollny; Theo M Bestebroer; Sabine Specht; Tasnim Suliman; Katrin Zimmermann; Tabea Binger; Isabella Eckerle; Marco Tschapka; Ali M Zaki; Albert D M E Osterhaus; Ron A M Fouchier; Bart L Haagmans; Christian Drosten
Journal:  mBio       Date:  2012-12-11       Impact factor: 7.867

5.  In Silico Prediction and Experimental Confirmation of HA Residues Conferring Enhanced Human Receptor Specificity of H5N1 Influenza A Viruses.

Authors:  Sonja Schmier; Ahmed Mostafa; Thomas Haarmann; Norbert Bannert; John Ziebuhr; Veljko Veljkovic; Ursula Dietrich; Stephan Pleschka
Journal:  Sci Rep       Date:  2015-06-19       Impact factor: 4.379

6.  The SARS-CoV-2 RNA-protein interactome in infected human cells.

Authors:  Nora Schmidt; Caleb A Lareau; Hasmik Keshishian; Sabina Ganskih; Cornelius Schneider; Thomas Hennig; Randy Melanson; Simone Werner; Yuanjie Wei; Matthias Zimmer; Jens Ade; Luisa Kirschner; Sebastian Zielinski; Lars Dölken; Eric S Lander; Neva Caliskan; Utz Fischer; Jörg Vogel; Steven A Carr; Jochen Bodem; Mathias Munschauer
Journal:  Nat Microbiol       Date:  2020-12-21       Impact factor: 17.745

7.  Susceptibility of ferrets, cats, dogs, and other domesticated animals to SARS-coronavirus 2.

Authors:  Jianzhong Shi; Zhiyuan Wen; Gongxun Zhong; Huanliang Yang; Chong Wang; Baoying Huang; Renqiang Liu; Xijun He; Lei Shuai; Ziruo Sun; Yubo Zhao; Peipei Liu; Libin Liang; Pengfei Cui; Jinliang Wang; Xianfeng Zhang; Yuntao Guan; Wenjie Tan; Guizhen Wu; Hualan Chen; Zhigao Bu
Journal:  Science       Date:  2020-04-08       Impact factor: 47.728

8.  Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses.

Authors:  Michael Letko; Andrea Marzi; Vincent Munster
Journal:  Nat Microbiol       Date:  2020-02-24       Impact factor: 17.745

9.  Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus.

Authors:  Wenhui Li; Michael J Moore; Natalya Vasilieva; Jianhua Sui; Swee Kee Wong; Michael A Berne; Mohan Somasundaran; John L Sullivan; Katherine Luzuriaga; Thomas C Greenough; Hyeryun Choe; Michael Farzan
Journal:  Nature       Date:  2003-11-27       Impact factor: 49.962

10.  Ultrastructural analysis of SARS-CoV-2 interactions with the host cell via high resolution scanning electron microscopy.

Authors:  Lucio Ayres Caldas; Fabiana Avila Carneiro; Luiza Mendonça Higa; Fábio Luiz Monteiro; Gustavo Peixoto da Silva; Luciana Jesus da Costa; Edison Luiz Durigon; Amilcar Tanuri; Wanderley de Souza
Journal:  Sci Rep       Date:  2020-09-30       Impact factor: 4.379

View more
  14 in total

Review 1.  Coronavirus Disease 2019-COVID-19.

Authors:  Kuldeep Dhama; Sharun Khan; Ruchi Tiwari; Shubhankar Sircar; Sudipta Bhat; Yashpal Singh Malik; Karam Pal Singh; Wanpen Chaicumpa; D Katterine Bonilla-Aldana; Alfonso J Rodriguez-Morales
Journal:  Clin Microbiol Rev       Date:  2020-06-24       Impact factor: 26.132

Review 2.  Update on treatment and preventive interventions against COVID-19: an overview of potential pharmacological agents and vaccines.

Authors:  Yinan Xiao; Hanyue Xu; Wen Guo; Yunuo Zhao; Yuling Luo; Ming Wang; Zhiyao He; Zhenyu Ding; Jiyan Liu; Lei Deng; Fushen Sha; Xuelei Ma
Journal:  Mol Biomed       Date:  2020-12-03

3.  Coronavirus infections reported by ProMED, February 2000-January 2020.

Authors:  D Katterine Bonilla-Aldana; Yeimer Holguin-Rivera; Isabella Cortes-Bonilla; María C Cardona-Trujillo; Alejandra García-Barco; Hugo A Bedoya-Arias; Ali A Rabaan; Ranjit Sah; Alfonso J Rodriguez-Morales
Journal:  Travel Med Infect Dis       Date:  2020-02-06       Impact factor: 6.211

Review 4.  Computational drug discovery and repurposing for the treatment of COVID-19: A systematic review.

Authors:  Kawthar Mohamed; Niloufar Yazdanpanah; Amene Saghazadeh; Nima Rezaei
Journal:  Bioorg Chem       Date:  2020-11-19       Impact factor: 5.275

Review 5.  Animal models for COVID-19.

Authors:  César Muñoz-Fontela; William E Dowling; Simon G P Funnell; Pierre-S Gsell; A Ximena Riveros-Balta; Randy A Albrecht; Hanne Andersen; Ralph S Baric; Miles W Carroll; Marco Cavaleri; Chuan Qin; Ian Crozier; Kai Dallmeier; Leon de Waal; Emmie de Wit; Leen Delang; Erik Dohm; W Paul Duprex; Darryl Falzarano; Courtney L Finch; Matthew B Frieman; Barney S Graham; Lisa E Gralinski; Kate Guilfoyle; Bart L Haagmans; Geraldine A Hamilton; Amy L Hartman; Sander Herfst; Suzanne J F Kaptein; William B Klimstra; Ivana Knezevic; Philip R Krause; Jens H Kuhn; Roger Le Grand; Mark G Lewis; Wen-Chun Liu; Pauline Maisonnasse; Anita K McElroy; Vincent Munster; Nadia Oreshkova; Angela L Rasmussen; Joana Rocha-Pereira; Barry Rockx; Estefanía Rodríguez; Thomas F Rogers; Francisco J Salguero; Michael Schotsaert; Koert J Stittelaar; Hendrik Jan Thibaut; Chien-Te Tseng; Júlia Vergara-Alert; Martin Beer; Trevor Brasel; Jasper F W Chan; Adolfo García-Sastre; Johan Neyts; Stanley Perlman; Douglas S Reed; Juergen A Richt; Chad J Roy; Joaquim Segalés; Seshadri S Vasan; Ana María Henao-Restrepo; Dan H Barouch
Journal:  Nature       Date:  2020-09-23       Impact factor: 49.962

6.  Virtual screenings of the bioactive constituents of tea, prickly chaff, catechu, lemon, black pepper, and synthetic compounds with the main protease (Mpro) and human angiotensin-converting enzyme 2 (ACE 2) of SARS-CoV-2.

Authors:  Nazim Uddin Emon; Md Munsur Alam; Irin Akter; Saima Akhter; Anjuman Ara Sneha; Md Irtiza; Marufa Afroj; Arifa Munni; Masruba Hossen Chowdhury; Summiya Hossain
Journal:  Futur J Pharm Sci       Date:  2021-06-15

Review 7.  COVID-19, an emerging coronavirus infection: advances and prospects in designing and developing vaccines, immunotherapeutics, and therapeutics.

Authors:  Kuldeep Dhama; Khan Sharun; Ruchi Tiwari; Maryam Dadar; Yashpal Singh Malik; Karam Pal Singh; Wanpen Chaicumpa
Journal:  Hum Vaccin Immunother       Date:  2020-03-18       Impact factor: 3.452

8.  The SARS-CoV-2 outbreak from a one health perspective.

Authors:  Maged Gomaa Hemida; Mohammed M Ba Abduallah
Journal:  One Health       Date:  2020-03-16

9.  Drug Repurposing for Candidate SARS-CoV-2 Main Protease Inhibitors by a Novel In Silico Method.

Authors:  Milan Sencanski; Vladimir Perovic; Snezana B Pajovic; Miroslav Adzic; Slobodan Paessler; Sanja Glisic
Journal:  Molecules       Date:  2020-08-23       Impact factor: 4.411

10.  Pigs are not susceptible to SARS-CoV-2 infection but are a model for viral immunogenicity studies.

Authors:  Júlia Vergara-Alert; Jordi Rodon; Jorge Carrillo; Nigeer Te; Nuria Izquierdo-Useros; María Luisa Rodríguez de la Concepción; Carlos Ávila-Nieto; Víctor Guallar; Alfonso Valencia; Guillermo Cantero; Julià Blanco; Bonaventura Clotet; Albert Bensaid; Joaquim Segalés
Journal:  Transbound Emerg Dis       Date:  2020-10-23       Impact factor: 4.521

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.